Duopharma Biotech Valuation
| 7148 Stock | 1.25 0.01 0.79% |
Today, the firm appears to be overvalued. Duopharma Biotech Bhd shows a prevailing Real Value of USD1.06 per share. The current price of the firm is USD1.25. Our model computes the value of Duopharma Biotech Bhd from reviewing the firm fundamentals such as Price To Book of 2.32 X, ebitda of 121.38 M, and Revenue of 639.17 M as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Duopharma Biotech's price fluctuation is very risky at this time. Calculation of the real value of Duopharma Biotech Bhd is based on 3 months time horizon. Increasing Duopharma Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Duopharma stock is determined by what a typical buyer is willing to pay for full or partial control of Duopharma Biotech Bhd. Since Duopharma Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Duopharma Stock. However, Duopharma Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.25 | Real 1.06 | Hype 1.25 | Naive 1.29 |
The intrinsic value of Duopharma Biotech's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Duopharma Biotech's stock price.
Estimating the potential upside or downside of Duopharma Biotech Bhd helps investors to forecast how Duopharma stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Duopharma Biotech more accurately as focusing exclusively on Duopharma Biotech's fundamentals will not take into account other important factors: Duopharma Biotech Total Value Analysis
Duopharma Biotech Bhd is presently forecasted to have takeover price of 1.78 B with market capitalization of 1.56 B, debt of 297.8 M, and cash on hands of 31.5 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Duopharma Biotech fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.78 B | 1.56 B | 297.8 M | 31.5 M |
Duopharma Biotech Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The latest return on assets of Duopharma suggests not a very effective usage of assets in November.Duopharma Biotech Profitability Analysis
The company reported the revenue of 639.17 M. Net Income was 82.98 M with profit before overhead, payroll, taxes, and interest of 0.About Duopharma Biotech Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Duopharma Biotech Bhd. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Duopharma Biotech Bhd based exclusively on its fundamental and basic technical indicators. By analyzing Duopharma Biotech's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Duopharma Biotech's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Duopharma Biotech. We calculate exposure to Duopharma Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Duopharma Biotech's related companies.8 Steps to conduct Duopharma Biotech's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Duopharma Biotech's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Duopharma Biotech's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Duopharma Biotech's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Duopharma Biotech's revenue streams: Identify Duopharma Biotech's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Duopharma Biotech's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Duopharma Biotech's growth potential: Evaluate Duopharma Biotech's management, business model, and growth potential.
- Determine Duopharma Biotech's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Duopharma Biotech's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Other Information on Investing in Duopharma Stock
Duopharma Biotech financial ratios help investors to determine whether Duopharma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Duopharma with respect to the benefits of owning Duopharma Biotech security.